Levodopa does not change cerebral vasoreactivity in Parkinson's disease.
Identifieur interne : 000071 ( France/Analysis ); précédent : 000070; suivant : 000072Levodopa does not change cerebral vasoreactivity in Parkinson's disease.
Auteurs : Alexandre Krainik [France] ; Audrey Maillet ; Vanessa Fleury ; Mehmet Sahin ; Irène Troprès ; Laurent Lamalle ; Stephane Thobois ; Valerie Fraix ; Marjorie Villien ; Jan Warnking ; Pierre Pollak ; Serge Pinto ; Paul KrackSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Female, Humans, Image Processing, Computer-Assisted, Levodopa (therapeutic use), Magnetic Resonance Imaging (methods), Male, Middle Aged, Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (pathology), Prospective Studies.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- methods : Magnetic Resonance Imaging.
- pathology : Parkinson Disease.
- Adult, Aged, Female, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Neuropsychological Tests, Prospective Studies.
- mix :
Abstract
The aim of this work was to study cerebral vasoreactivity to hypercapnia in Parkinson's disease (PD) before and after levodopa administration. The prospective study was conducted in 20 patients presenting with PD, using 3T blood oxygenation level-dependent (BOLD) functional MRI (fMRI) covering the whole brain. The hypercapnic stimulus was block-designed using carbogen inhalation, a gas mixture of 7% CO2 and 93% O2, before (OFF) and 60 minutes after administration of a suprathreshold (120%) therapeutic L-dopa dose (ON). Ten age-matched controls were enrolled for between-group comparisons. Analyses were conducted with a random effects model and corrected for multiple comparisons. No adverse reaction to the hypercapnic stimulus was reported. However, 10 patients and 2 controls were excluded because of incomplete protocol realization, inappropriate hypercapnic stimulus, or excessive movements, leaving 10 patients and 8 controls for further analyses. The hypercapnic stimulus increased whole-brain BOLD signal of 1.48% ± 0.06% (mean ± standard error) in controls, 1.59% ± 0.05% in patients OFF, and 1.62% ± 0.09% in patients ON. Regions of interest analyses showed a signal increase in gray matter of 2.60% ± 0.16% in controls, 2.89% ± 0.21% in patients OFF, and 2.87% ± 0.12% in patients ON. No global or regional significant difference was detected, when comparing patients OFF and ON L-dopa, or between patients and controls. Contrary to Alzheimer's disease, the vasoreactivity to hypercapnia was normal in PD before and after L-dopa administration, compared to controls. This negative result is an important finding, especially for neuroscientists using fMRI to investigate motricity and cognition, discarding a significant confounding effect.
Url:
DOI: 10.1002/mds.25267
PubMed: 23238963
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B34
- to stream PubMed, to step Curation: 000B34
- to stream PubMed, to step Checkpoint: 000953
- to stream Ncbi, to step Merge: 003929
- to stream Ncbi, to step Curation: 003929
- to stream Ncbi, to step Checkpoint: 003929
- to stream Hal, to step Corpus: 000038
- to stream Hal, to step Curation: 000038
- to stream Hal, to step Checkpoint: 000006
- to stream Main, to step Merge: 000939
- to stream Main, to step Curation: 000939
- to stream Main, to step Exploration: 000939
- to stream France, to step Extraction: 000071
Links to Exploration step
pubmed:23238963Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa does not change cerebral vasoreactivity in Parkinson's disease.</title><author><name sortKey="Krainik, Alexandre" sort="Krainik, Alexandre" uniqKey="Krainik A" first="Alexandre" last="Krainik">Alexandre Krainik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neuroradiology and MRI, University Hospital of Grenoble, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neuroradiology and MRI, University Hospital of Grenoble, Grenoble</wicri:regionArea><placeName><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Maillet, Audrey" sort="Maillet, Audrey" uniqKey="Maillet A" first="Audrey" last="Maillet">Audrey Maillet</name></author><author><name sortKey="Fleury, Vanessa" sort="Fleury, Vanessa" uniqKey="Fleury V" first="Vanessa" last="Fleury">Vanessa Fleury</name></author><author><name sortKey="Sahin, Mehmet" sort="Sahin, Mehmet" uniqKey="Sahin M" first="Mehmet" last="Sahin">Mehmet Sahin</name></author><author><name sortKey="Tropres, Irene" sort="Tropres, Irene" uniqKey="Tropres I" first="Irène" last="Troprès">Irène Troprès</name></author><author><name sortKey="Lamalle, Laurent" sort="Lamalle, Laurent" uniqKey="Lamalle L" first="Laurent" last="Lamalle">Laurent Lamalle</name></author><author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stephane" last="Thobois">Stephane Thobois</name></author><author><name sortKey="Fraix, Valerie" sort="Fraix, Valerie" uniqKey="Fraix V" first="Valerie" last="Fraix">Valerie Fraix</name></author><author><name sortKey="Villien, Marjorie" sort="Villien, Marjorie" uniqKey="Villien M" first="Marjorie" last="Villien">Marjorie Villien</name></author><author><name sortKey="Warnking, Jan" sort="Warnking, Jan" uniqKey="Warnking J" first="Jan" last="Warnking">Jan Warnking</name></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name></author><author><name sortKey="Pinto, Serge" sort="Pinto, Serge" uniqKey="Pinto S" first="Serge" last="Pinto">Serge Pinto</name></author><author><name sortKey="Krack, Paul" sort="Krack, Paul" uniqKey="Krack P" first="Paul" last="Krack">Paul Krack</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="doi">10.1002/mds.25267</idno><idno type="RBID">pubmed:23238963</idno><idno type="pmid">23238963</idno><idno type="wicri:Area/PubMed/Corpus">000B34</idno><idno type="wicri:Area/PubMed/Curation">000B34</idno><idno type="wicri:Area/PubMed/Checkpoint">000953</idno><idno type="wicri:Area/Ncbi/Merge">003929</idno><idno type="wicri:Area/Ncbi/Curation">003929</idno><idno type="wicri:Area/Ncbi/Checkpoint">003929</idno><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:inserm-00861162</idno><idno type="url">http://www.hal.inserm.fr/inserm-00861162</idno><idno type="wicri:Area/Hal/Corpus">000038</idno><idno type="wicri:Area/Hal/Curation">000038</idno><idno type="wicri:Area/Hal/Checkpoint">000006</idno><idno type="wicri:doubleKey">0885-3185:2013:Krainik A:levodopa:does:not</idno><idno type="wicri:Area/Main/Merge">000939</idno><idno type="wicri:Area/Main/Curation">000939</idno><idno type="wicri:Area/Main/Exploration">000939</idno><idno type="wicri:Area/France/Extraction">000071</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa does not change cerebral vasoreactivity in Parkinson's disease.</title><author><name sortKey="Krainik, Alexandre" sort="Krainik, Alexandre" uniqKey="Krainik A" first="Alexandre" last="Krainik">Alexandre Krainik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neuroradiology and MRI, University Hospital of Grenoble, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neuroradiology and MRI, University Hospital of Grenoble, Grenoble</wicri:regionArea><placeName><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Maillet, Audrey" sort="Maillet, Audrey" uniqKey="Maillet A" first="Audrey" last="Maillet">Audrey Maillet</name></author><author><name sortKey="Fleury, Vanessa" sort="Fleury, Vanessa" uniqKey="Fleury V" first="Vanessa" last="Fleury">Vanessa Fleury</name></author><author><name sortKey="Sahin, Mehmet" sort="Sahin, Mehmet" uniqKey="Sahin M" first="Mehmet" last="Sahin">Mehmet Sahin</name></author><author><name sortKey="Tropres, Irene" sort="Tropres, Irene" uniqKey="Tropres I" first="Irène" last="Troprès">Irène Troprès</name></author><author><name sortKey="Lamalle, Laurent" sort="Lamalle, Laurent" uniqKey="Lamalle L" first="Laurent" last="Lamalle">Laurent Lamalle</name></author><author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stephane" last="Thobois">Stephane Thobois</name></author><author><name sortKey="Fraix, Valerie" sort="Fraix, Valerie" uniqKey="Fraix V" first="Valerie" last="Fraix">Valerie Fraix</name></author><author><name sortKey="Villien, Marjorie" sort="Villien, Marjorie" uniqKey="Villien M" first="Marjorie" last="Villien">Marjorie Villien</name></author><author><name sortKey="Warnking, Jan" sort="Warnking, Jan" uniqKey="Warnking J" first="Jan" last="Warnking">Jan Warnking</name></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name></author><author><name sortKey="Pinto, Serge" sort="Pinto, Serge" uniqKey="Pinto S" first="Serge" last="Pinto">Serge Pinto</name></author><author><name sortKey="Krack, Paul" sort="Krack, Paul" uniqKey="Krack P" first="Paul" last="Krack">Paul Krack</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Imaging (methods)</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Prospective Studies</term></keywords><keywords scheme="mix" xml:lang="en"><term>BOLD fMRI</term><term>L-dopa</term><term>Parkinson's disease</term><term>carbon dioxide</term><term>cerebral vasoreactivity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this work was to study cerebral vasoreactivity to hypercapnia in Parkinson's disease (PD) before and after levodopa administration. The prospective study was conducted in 20 patients presenting with PD, using 3T blood oxygenation level-dependent (BOLD) functional MRI (fMRI) covering the whole brain. The hypercapnic stimulus was block-designed using carbogen inhalation, a gas mixture of 7% CO2 and 93% O2, before (OFF) and 60 minutes after administration of a suprathreshold (120%) therapeutic L-dopa dose (ON). Ten age-matched controls were enrolled for between-group comparisons. Analyses were conducted with a random effects model and corrected for multiple comparisons. No adverse reaction to the hypercapnic stimulus was reported. However, 10 patients and 2 controls were excluded because of incomplete protocol realization, inappropriate hypercapnic stimulus, or excessive movements, leaving 10 patients and 8 controls for further analyses. The hypercapnic stimulus increased whole-brain BOLD signal of 1.48% ± 0.06% (mean ± standard error) in controls, 1.59% ± 0.05% in patients OFF, and 1.62% ± 0.09% in patients ON. Regions of interest analyses showed a signal increase in gray matter of 2.60% ± 0.16% in controls, 2.89% ± 0.21% in patients OFF, and 2.87% ± 0.12% in patients ON. No global or regional significant difference was detected, when comparing patients OFF and ON L-dopa, or between patients and controls. Contrary to Alzheimer's disease, the vasoreactivity to hypercapnia was normal in PD before and after L-dopa administration, compared to controls. This negative result is an important finding, especially for neuroscientists using fMRI to investigate motricity and cognition, discarding a significant confounding effect.</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Grenoble</li></settlement></list><tree><noCountry><name sortKey="Fleury, Vanessa" sort="Fleury, Vanessa" uniqKey="Fleury V" first="Vanessa" last="Fleury">Vanessa Fleury</name><name sortKey="Fraix, Valerie" sort="Fraix, Valerie" uniqKey="Fraix V" first="Valerie" last="Fraix">Valerie Fraix</name><name sortKey="Krack, Paul" sort="Krack, Paul" uniqKey="Krack P" first="Paul" last="Krack">Paul Krack</name><name sortKey="Lamalle, Laurent" sort="Lamalle, Laurent" uniqKey="Lamalle L" first="Laurent" last="Lamalle">Laurent Lamalle</name><name sortKey="Maillet, Audrey" sort="Maillet, Audrey" uniqKey="Maillet A" first="Audrey" last="Maillet">Audrey Maillet</name><name sortKey="Pinto, Serge" sort="Pinto, Serge" uniqKey="Pinto S" first="Serge" last="Pinto">Serge Pinto</name><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><name sortKey="Sahin, Mehmet" sort="Sahin, Mehmet" uniqKey="Sahin M" first="Mehmet" last="Sahin">Mehmet Sahin</name><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stephane" last="Thobois">Stephane Thobois</name><name sortKey="Tropres, Irene" sort="Tropres, Irene" uniqKey="Tropres I" first="Irène" last="Troprès">Irène Troprès</name><name sortKey="Villien, Marjorie" sort="Villien, Marjorie" uniqKey="Villien M" first="Marjorie" last="Villien">Marjorie Villien</name><name sortKey="Warnking, Jan" sort="Warnking, Jan" uniqKey="Warnking J" first="Jan" last="Warnking">Jan Warnking</name></noCountry><country name="France"><noRegion><name sortKey="Krainik, Alexandre" sort="Krainik, Alexandre" uniqKey="Krainik A" first="Alexandre" last="Krainik">Alexandre Krainik</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000071 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000071 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= pubmed:23238963
|texte= Levodopa does not change cerebral vasoreactivity in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:23238963" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |